Bone Biologics Corporation (BBLG)

NASDAQ: BBLG · Real-Time Price · USD
3.020
-0.100 (-3.21%)
At close: Jul 10, 2025, 4:00 PM
3.000
-0.020 (-0.66%)
Pre-market: Jul 11, 2025, 8:18 AM EDT
-3.21%
Market Cap 4.85M
Revenue (ttm) n/a
Net Income (ttm) -7.48M
Shares Out 1.61M
EPS (ttm) -20.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 94,582
Open 3.150
Previous Close 3.120
Day's Range 3.010 - 3.179
52-Week Range 2.870 - 25.500
Beta 1.22
Analysts n/a
Price Target n/a
Earnings Date Aug 8, 2025

About BBLG

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company’s lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company’s NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interven... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2004
Employees 2
Stock Exchange NASDAQ
Ticker Symbol BBLG
Full Company Profile

Financial Performance

Financial Statements

News

Bone Biologics Announces Closing of $5.0 Million Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...

10 days ago - Business Wire

Why Is Bone Biologics Stock Surging On Friday?

Bone Biologics Corporation BBLG stock is trading higher on Friday, with a session volume of 17.22 million compared to the average volume of 38.795K as per data from Benzinga Pro.

13 days ago - Benzinga

Bone Biologics Announces Pricing of $5.0 Million Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...

13 days ago - Business Wire

Bone Biologics Files Patent Application for Bone Regeneration Technology

BURLINGTON, Mass.--(BUSINESS WIRE)---- $BBLG #Bonebiologics--Bone Biologics files U.S. patent application for bone regeneration technology.

14 days ago - Business Wire

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...

14 days ago - Business Wire

Bone Biologics Announces 1-for-6 Reverse Stock Split

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...

5 weeks ago - Business Wire

Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the ...

9 months ago - Business Wire

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that...

11 months ago - Business Wire

Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...

1 year ago - Business Wire

First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that...

1 year ago - Business Wire

Bone Biologics Announces Closing of $2.0 Million Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...

1 year ago - Business Wire

Bone Biologics Announces Pricing of $2.0 Million Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...

1 year ago - Business Wire

Bone Biologics Reports Progress With NB1 Clinical Program

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1...

1 year ago - Business Wire

Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...

1 year ago - Business Wire

Bone Biologics Announces 1-for-8 Reverse Stock Split

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...

1 year ago - Business Wire

Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced r...

1 year ago - Business Wire

Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agr...

1 year ago - Business Wire

Bone Biologics Provides Scientific Update on NB1 Bone Graft Device

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiative...

1 year ago - Business Wire

Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month - Bone Biologics (NASDAQ:BBLG), Fresh2 Group (NASDAQ:FRES)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: VTGN
2 years ago - Benzinga

Bone Biologics stock plummets more than 50% after stock offering prices at deep discount

Shares of Bone Biologics Corp. BBLG plummeted 51.9% toward a record low in premarket trading Thursday, after the developer of regenerative medicine for bones announced the pricing of its relatively la...

2 years ago - Market Watch

Bone Biologics Prices $5.0 Million Underwritten Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced the p...

2 years ago - Business Wire

Bone Biologics Effects 1-for-30 Reverse Stock Split

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that a 1-for-30 reverse stock split became effe...

2 years ago - Business Wire

Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC)...

2 years ago - Business Wire

Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has engaged Avania as the contract researc...

2 years ago - Business Wire

Bone Biologics CEO Issues Letter to Stockholders

BURLINGTON, Mass.

2 years ago - Business Wire